BBHC
KNSA icon

Brown Brothers Harriman & Co’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-333
Closed -$6.59K – 1391
2024
Q4 		$6.59K Hold
333
– – ﹤0.01% 1185
2024
Q3 		$8.32K Buy
+333
New +$8.11K ﹤0.01% 1083

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Brothers Harriman & Co's KNSA Position: Q1 2025 in Review

Brown Brothers Harriman & Co sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 333 shares — an estimated $6.59K sold.

Brown Brothers Harriman & Co first reported a position in KNSA in Q3 2024 and held it in 2 quarters. The position peaked at $8.32K in Q3 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • Brown Brothers Harriman & Co reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 333 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $6.59K.
  • Brown Brothers Harriman & Co first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Brown Brothers Harriman & Co's Kiniksa Pharmaceuticals position peaked at $8.32K in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2025, filed 14 May 2025.